New drug could cut repeat eye surgeries in diabetics
NCT ID NCT06191094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug farcimab (Vabysmo), given as an injection before and after eye surgery, can reduce bleeding complications in people with diabetes who have bleeding inside the eye. About 100 adults will receive either farcimab or a sham injection. The goal is to see if farcimab lowers the chance of needing another surgery and helps improve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
farcimab (Vabysmo) injection
What this could lead to
If it works, this could reduce the need for repeat surgeries and improve vision recovery in diabetic patients with eye bleeding.
What could go wrong
This is a small, early-phase trial with only 100 participants. The drug may not reduce bleeding better than sham, and there are risks from the injection itself, such as infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sue Anschutz-Rodgers Eye Center
Aurora, Colorado, 80045, United States